Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001549595-25-000101

Chief Financial Officer sold 4,304 shares at $12.01 ($51,695)

  • Chief Financial Officer acquired 11,494 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

van Houte Hans · Chief Financial Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2025-07-30 Exercise or conversion : show line 1 in the form +2,886 36,610 D
2025-07-30 Exercise or conversion : show line 2 in the form +2,000 38,610 D
2025-07-30 Exercise or conversion : show line 3 in the form +3,750 42,360 D
2025-07-30 Exercise or conversion : show line 4 in the form +2,858 45,218 D
2025-07-30 Sale : show line 5 in the form −4,304 $12.01 $51,695 40,914 D
Open-market sales · 4,304 sh · avg $12.01 · $51,695

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2025-07-30 Exercise or conversion : show line 6 in the form Restricted Stock Units −2,886 5,773 D
2025-07-30 Exercise or conversion : show line 7 in the form Restricted Stock Units −2,000 6,000 D
2025-07-30 Exercise or conversion : show line 8 in the form Restricted Stock Units −3,750 26,250 D
2025-07-30 Exercise or conversion : show line 9 in the form Restricted Stock Units −2,858 31,442 D
Loading xslF345X05/wk-form4_1753915745.xml…